George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 100.00
Bid: 90.00
Ask: 110.00
Change: 0.00 (0.00%)
Spread: 20.00 (22.222%)
Open: 100.00
High: 100.00
Low: 100.00
Prev. Close: 100.00
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-close Trading Statement

25 Jan 2018 07:00

RNS Number : 8506C
Biome Technologies PLC
25 January 2018
 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR")

 

 

25 January 2018

Biome Technologies plc

 ("Biome", "the Company" or "the Group")

 

Pre-close Trading Statement

 

 

Biome Technologies plc's pre-close trading statement for the financial year ended 31 December 2017 is set out below.

 

Group revenues for the year were £6.2m, 36% ahead of the 2016 revenues of £4.6m.

 

Revenues in the Bioplastics division were £2.3m, an increase of 44% on 2016 revenues of £1.6m. The Bioplastics division benefitted from an increase in the use of its material for the coffee market following the commercialisation of the innovative BiomeMesh filter material. The shifting perception of plastic waste both in public opinion and amongst policy-makers, particularly in the UK, provides encouragement for future growth in the use of bioplastic products.

 

The RF division also had a strong year with revenues of £4.0m, an increase of 32% over 2016 revenues of £3.0m. The increase in revenues is attributable mainly to robust demand for the fibre optic furnace products underpinned by the roll out of infrastructure investment in telecommunications, including "5G", in Asia. As 2018 commences, the RF division has a strong order book which is ahead of that at the comparable point in 2017.

 

The Group's cash position at 31 December 2017 was £2.3m (30 September 2017: £2.4m; 31 December 2016: £1.5m). The increase in cash year on year is a mixture of trading performance, working capital movements and the £0.45m received under the previously reported settlement agreement.

 

The Board expects that the Group will record a small profit before interest, tax, depreciation, amortisation, and share option charges ("EBITDA") for the 2017 financial year (2016: trading EBITDA loss of £0.2m excluding the settlement agreement).

 

The audited results for the year ended 31 December 2017 are scheduled to be published on 27 March 2018.

 

 

-Ends-

 

 

 

 

 

For further information please contact: Biome Technologies plc

 

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Chris Crawford/Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDZLFLVFFXBBQ
Date   Source Headline
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular
1st Aug 20057:01 amRNSDirector Appointment
28th Jul 20057:01 amRNSUpdate re: trials with ASDA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.